CCO Annual Update
Breast Cancer Annual Update 2005
Advances in Breast Cancer Screening and Imaging |
Module 1 of 12 |
|
Program Director: Clifford A. Hudis, MD
|
|
Topics covered include:
- Introduction
- Digital Mammography Systems
- Digital Mammography vs Screen Film Mammography
- Telemammography
- Advanced Applications of Digital Mammography
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss novel and emerging techniques for detecting and imaging breast cancer. Describe study results comparing newer techniques with screen-film mammography. Recount the indications for using ultrasound, magnetic resonance imaging, and positron emission tomography scanning in breast cancer imaging.
|
Inherited Susceptibility to Breast Cancer |
Module 2 of 12 |
|
Program Director: Clifford A. Hudis, MD
|
|
Topics covered include:
- Introduction
- Prevalence and Epidemiology of BRCA Mutations
- Genetic Risk of Cancer
- Management of BRCA-Associated Cancer
- Management of Risk in Unaffected Women Carrying Mutations
Learning Objectives
Upon completion of this activity, participants should be able to:
Review management of breast cancer risk in unaffected women who carry BRCA1 and BRCA2. Evaluate the risk of cancer and potential clinical impact conferred by each gene. Distinguish between BRCA1 and BRCA2, the genes most commonly associated with hereditary breast cancer, in terms of prevalence and epidemiology.
|
Changes in Staging Classification for Breast Cancer 2005 |
Module 3 of 12 |
|
Program Director: Clifford A. Hudis, MD
- S. Eva Singletary, MD, FACS
|
|
|
Topics covered include:
- Introduction
- Descriptors in the TNM Staging System
- Impact of ITCs and Micrometastases on Outcome
- Impact of Location of Lymph Node Metastases
- Impact of Location of Lymph Node Metastases
Learning Objectives
Upon completion of this activity, participants should be able to:
Identify areas of potential change for the future, based on technologic advances and ongoing clinical research. Explain the rationale for these changes in staging, based on current scientific literature. Describe recent changes in the staging of breast cancer, based on updates to the American Joint Committee on Cancer Staging Manual.
|
Sentinel Lymph Nodes in Breast Cancer: Evolving Indications |
Module 4 of 12 |
|
CME Program Director: Clifford A. Hudis, MD
 
- Armando E. Giuliano, MD
- Helen Mabry, MD
|
|
|
Topics covered include:
- Introduction
- Methodology of SNB
- Indications for SNB
- Contraindications for SNB
- SNB Prior to Surgery
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate the role of sentinel lymph node biopsies vs standard axillary lymph node dissections in staging for breast cancer, based on recent findings from clinical trials
- Review indications and contraindications for use of sentinel lymph node biopsies in early-stage breast cancer
- Compare techniques for sentinel lymph node biopsies
|
Neoadjuvant Treatment for Breast Cancer |
Module 5 of 12 |
|
CME Program Director: Clifford A. Hudis, MD
|
|
Topics covered include:
- Introduction
- Outcomes—Neoadjuvant vs Adjuvant Chemotherapy
- Taxane-Based Regimens in the Neoadjuvant Setting
- Aromatase Inhibitors in the Neoadjuvant Setting
- Targeted Therapy
Learning Objectives
Upon completion of this activity, participants should be able to:
- Compare the advantages and disadvantages of neoadjuvant vs adjuvant therapy.
- Describe the most recent data using newer agents, including aromatase inhibitors and targeted therapies, in the neoadjuvant setting.
- Discuss molecular predictors of response to neoadjuvant therapy.
|
Update on Adjuvant Hormonal Therapy for Breast Cancer |
Module 6 of 12 |
|
Program Director: Clifford A. Hudis, MD
|
|
Topics covered include:
- Introduction
- Tamoxifen
- Aromatase Inhibitors: Options for Postmenopausal Women
- Aromatase Inhibitors as Initial Adjuvant Therapy
- Sequential Therapy with Tamoxifen and an Aromatase Inhibitor
Learning Objectives
Upon completion of this activity, participants should be able to:
Evaluate the relative efficacy and safety of tamoxifen, anastrozole, letrozole, and exemestane. Describe the role of adjuvant hormonal therapy in breast cancer, with particular regard for differing patient characteristics. Review the most recent data from pivotal hormonal therapy trials in women with breast cancer.
|
Nonhormonal Adjuvant Therapy for Breast Cancer |
Module 7 of 12 |
|
Program Director: Clifford A. Hudis, MD
|
|
Topics covered include:
- Introduction
- Early Use of Adjuvant Chemotherapy for Breast Cancer
- Taxanes: Adjuvant Trials From 1990-2000
- Adjuvant Trastuzumab
- Conclusions
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the role of taxanes in early-stage breast cancer, particularly with regard to patient selection, dosing regimens, and scheduling. Review the efficacy and safety of cyclophosphamide, methotrexate, 5-fluorouracil (CMF), and anthracycline-containing cytotoxic regimens in early-stage breast cancer. Evaluate recent data on the efficacy and safety of trastuzumab in combination with cytotoxic chemotherapy as adjuvant treatment for early-stage breast cancer.
|
Important Advances in the Role of Trastuzumab in Breast Cancer |
Module 8 of 12 |
|
CME Program Director: Clifford A. Hudis, MD
|
|
Topics covered include:
- Introduction
- Antibody-Dependent Cell-Mediated Cytotoxicity and Antibody Activity
- Trastuzumab for Metastatic Breast Cancer
- Clinical Efficacy of Trastuzumab in the Adjuvant Setting
- Safety of Trastuzumab
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the various mechanisms of action by which trastuzumab works in the treatment of breast cancer.
- Discuss recent clinical trial data regarding use of trastuzumab in the adjuvant treatment of breast cancer.
- Review mechanisms of resistance to trastuzumab.
|
Incorporating New Agents in Advanced Breast Cancer |
Module 9 of 12 |
|
Program Director: Clifford A. Hudis, MD
 
- Bryan Schneider, MD
- George W. Sledge, Jr., MD
|
|
|
Topics covered include:
- Introduction
- Agents That Target HER-2
- Agents That Target HER-2: Trastuzumab
- Agents That Target HER-2: Lapatinib (GW572016)
- Agents Directed at Tumor Angiogenesis: Bevacizumab
Learning Objectives
Upon completion of this activity, participants should be able to:
Evaluate relative efficacy and safety of novel agents in advanced breast cancer Review results of recent studies of trastuzumab and bevacizumab in advanced breast cancer Describe novel targeted and cytotoxic agents for breast cancer
|
Emerging Biology of Breast Cancer: Circulating Tumor Cells |
Module 10 of 12 |
|
Program Director: Clifford A. Hudis, MD
 
- Daniel F. Hayes, MD
- Jeffrey B. Smerage, MD, PhD
|
|
|
Topics covered include:
- Introduction
- Technologies for CTC Detection
- CTC Counts as Prognostic Factors in Breast Cancer
- Role of CTC Counts in Monitoring Therapy
- CTC Biology
Learning Objectives
Upon completion of this activity, participants should be able to:
Identify obstacles in collecting, analyzing, and interpreting data from circulating tumor cell assays. Describe methods used to detect circulating tumor cells in peripheral blood. Evaluate circulating tumor cells as prognostic factors in metastatic breast cancer.
|
Genomics-based Prognostic and Predictive Markers: Are They Ready for Prime Time? |
Module 11 of 12 |
|
CME Program Director: Clifford A. Hudis, MD
|
|
Topics covered include:
- Introduction
- Utility of Molecular Markers
- Gene Expression Profiling Methods
- Interpreting Gene Expression Profiles
- Development and Validation of OncotypeDx Assay
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe microassay methods used to identify molecular markers
- Discuss role of known molecular markers in assessing risk of recurrence
- Identify challenges in collecting, analyzing, and interpreting data from microassays
|
Supportive Care for Breast Cancer |
Module 12 of 12 |
|
Program Director: Clifford A. Hudis, MD
 
- Clifford A. Hudis, MD
- Robert S. Mocharnuk, MD
|
|
|
Topics covered include:
- Introduction
- Managing Bone Health in Women With Breast Cancer
- Fatigue and Cognitive Impairment
- Management of Menopausal Symptoms
- Prevention and Management of Neutropenia
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the causes and complications of fatigue and cognitive impairment in women with breast cancer Assess the efficacy of current treatment options for chemotherapy-induced nausea and vomiting Compare strategies for the prevention and management of treatment-induced cytopenias. Review current treatment options for management of menopausal symptoms in women with breast cancer Evaluate pharmacologic options for management of treatment-related osteoporosis and/or osteopenia
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
|